ID   OVCAR3-533533-R1
AC   CVCL_DH37
SY   533533-R1
DR   cancercelllines; CVCL_DH37
DR   GEO; GSM1186817
DR   GEO; GSM1186822
DR   GEO; GSM1186828
DR   Progenetix; CVCL_DH37
DR   Wikidata; Q54937018
RX   PubMed=24004674;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_132239; PHA-533533.
CC   Sequence variation: Mutation; HGNC; HGNC:8979; PIK3R1; Simple; c.1746-2A>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0465 ! OVCAR-3
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 19-12-24; Version: 13
//
RX   PubMed=24004674; DOI=10.1158/1078-0432.CCR-13-1337;
RA   Etemadmoghadam, Dariush
RA   Au-Yeung, George
RA   Wall, Meaghan
RA   Mitchell, Chris
RA   Kansara, Maya
RA   Loehrer, Elizabeth
RA   Batzios, Crisoula
RA   George, Joshy
RA   Ftouni, Sarah
RA   Weir, Barbara A.
RA   Carter, Scott
RA   Gresshoff, Irma L.
RA   Mileshkin, Linda
RA   Rischin, Danny
RA   Hahn, William Chun
RA   Waring, Paul M.
RA   Getz, Gad
RA   Cullinane, Carleen
RA   Campbell, Lynda J.
RA   Bowtell, David D.L.
RT   "Resistance to CDK2 inhibitors is associated with selection of
RT   polyploid cells in CCNE1-amplified ovarian cancer.";
RL   Clin. Cancer Res. 19:5960-5971(2013).
//